+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Atherosclerotic Cardiovascular Disease (ASCVD) Pipeline Analysis Report 2025- Product Image
Atherosclerotic Cardiovascular Disease (ASCVD) Pipeline Analysis Report 2025- Product Image
New

Atherosclerotic Cardiovascular Disease (ASCVD) Pipeline Analysis Report 2025

  • PDF Icon

    Report

  • 200 Pages
  • June 2025
  • Region: Global
  • Expert Market Research
  • ID: 6102858
Description Jump to:
Cardiovascular disease stands as the leading cause of mortality and morbidity, with more than 523 million individuals affected by the condition. Atherosclerotic cardiovascular disease, especially ischemic heart disease and stroke, contributes to a significant disease burden and poses serious implications for health systems and resource availability. Thus, the rising cases of atherosclerotic cardiovascular disease coupled with the substantial investment in research and development (R&D) by pharmaceutical companies are anticipated to boost the growth of the drug pipeline in the coming years.

Report Coverage

The Atherosclerotic Cardiovascular Disease (ASCVD) Drug Pipeline Insight Report by the publisher gives comprehensive insights into atherosclerotic cardiovascular disease (ASCVD) therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Atherosclerotic Cardiovascular Disease (ASCVD). The atherosclerotic cardiovascular disease (ASCVD) report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The atherosclerotic cardiovascular disease (ASCVD) pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with atherosclerotic cardiovascular disease (ASCVD) treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to atherosclerotic cardiovascular disease (ASCVD).

Atherosclerotic Cardiovascular Disease (ASCVD) Drug Pipeline Outlook

Atherosclerotic cardiovascular disease refers to a chronic condition caused by the buildup of plaque in the walls of arteries, leading to the narrowing of blood flow and consequently reduction in the oxygen supply to the body. Common symptoms include chest pain, weakness, shortness of breath, and pain in the arms or legs, among others. Atherosclerotic cardiovascular disease can start as early as childhood. However, it develops gradually over time and may progress into a heart attack or angina.

Atherosclerotic cardiovascular disease (ASCVD) therapeutics include statins, anticoagulants (or blood thinners), and antiplatelet medicines. Antiplatelet drugs, such as ticlopidine, aspirin, clopidogrel, and dipyridamole, help in decreasing the ability of platelets to stick together, thereby preventing clots. Further, the rising regulatory support for atherosclerotic cardiovascular disease (ASCVD) emerging drugs, including RNA-based and gene therapies, along with the growing aging population, is expected to support the pipeline expansion in the coming years.

Atherosclerotic Cardiovascular Disease (ASCVD) Epidemiology

Cardiovascular disease affects more than 523 million people worldwide. Various studies reveal atherosclerotic cardiovascular diseases, especially stroke and ischemic heart disease, account for a significant cardiovascular disease burden. It is estimated that ischemic heart disease contributes to around half of the total cardiovascular disease-related deaths, whereas a quarter is attributed to ischemic stroke.

Atherosclerotic Cardiovascular Disease (ASCVD) - Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of atherosclerotic cardiovascular disease (ASCVD) drug candidates based on several segmentations including:

By Phase

  • Late-Stage Products (Phase 3 and Phase 4)
  • Mid-Stage Products (Phase 2)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products

By Drug Class

  • Small Molecules
  • Monoclonal Antibodies
  • RNA-Based Therapies
  • Gene Therapies
  • Peptide-Based Therapies
  • Vaccines
  • Natural Product Derivatives
  • Combination Therapies

By Route of Administration

  • Oral
  • Parenteral
  • Others

Atherosclerotic Cardiovascular Disease (ASCVD) - Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase III covers a major share of the total clinical trials, with an estimated 43 atherosclerotic cardiovascular disease (ASCVD) drugs undergoing clinical development.

Atherosclerotic Cardiovascular Disease (ASCVD) - Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under atherosclerotic cardiovascular disease (ASCVD) pipeline analysis include small molecules, monoclonal antibodies, RNA-based therapies, gene therapies, peptide-based therapies, vaccines, natural product derivatives, and combination therapies. The atherosclerotic cardiovascular disease (ASCVD) report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for atherosclerotic cardiovascular disease (ASCVD).

Atherosclerotic Cardiovascular Disease (ASCVD) Clinical Trials Therapeutic Assessment - Competitive Dynamics

The report for the atherosclerotic cardiovascular disease (ASCVD) drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed atherosclerotic cardiovascular disease (ASCVD) therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. below is the list of a few players involved in atherosclerotic cardiovascular disease (ASCVD) clinical trials:
  • Amgen
  • AstraZeneca
  • Novartis Pharmaceuticals
  • NewAmsterdam Pharma
  • CSL Behring
  • Verve Therapeutics, Inc.

Atherosclerotic Cardiovascular Disease (ASCVD) - Emerging Drugs Profile

Major drugs currently in the drug pipeline are as follows:

Drug: Obicetrapib

Sponsored by NewAmsterdam Pharma, the objective of this randomized clinical trial is to investigate the efficacy and safety of the atherosclerotic cardiovascular disease (ASCVD) drug candidate Obicetrapib in patients who didn’t show adequate response to maximally tolerated lipid-lowering therapy. The study is under Phase III clinical development and has an estimated 9541 participants.

Drug: Olpasiran

Amgen is conducting a Phase III study aimed at examining the efficacy of the investigational drug Olpasiran on the risk for myocardial infarction, coronary heart disease death, or urgent coronary revascularization in patients with atherosclerotic cardiovascular disease and elevated Lipoprotein(a). The interventional study has enrolled about 7297 subjects and is expected to be completed by December 2026.

Reasons To Buy This Report

The Atherosclerotic Cardiovascular Disease (ASCVD) Drug Report provides a strategic overview of the latest and future landscape of treatments for atherosclerotic cardiovascular disease (ASCVD). it provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within atherosclerotic cardiovascular disease (ASCVD) pipeline insights.

Key Questions Answered in the Atherosclerotic Cardiovascular Disease (ASCVD) - Pipeline Insight Report

  • What is the current landscape of atherosclerotic cardiovascular disease (ASCVD) disease pipeline drugs?
  • Which companies/institutions are developing atherosclerotic cardiovascular disease (ASCVD) disease emerging drugs?
  • How many phase II drugs are currently present in Atherosclerotic Cardiovascular Disease (ASCVD) disease pipeline drugs?
  • Which company is leading the atherosclerotic cardiovascular disease (ASCVD) disease pipeline development activities?
  • What is the current atherosclerotic cardiovascular disease (ASCVD) disease therapeutic assessment?
  • What are the opportunities and challenges present in the atherosclerotic cardiovascular disease (ASCVD) disease drug pipeline landscape?
  • What is the efficacy and safety profile of atherosclerotic cardiovascular disease (ASCVD) disease pipeline drugs?
  • Which companies/institutions are involved in atherosclerotic cardiovascular disease (ASCVD) disease collaborations aimed at providing enhanced therapeutic alternatives for patients?
  • What are the geographies covered for clinical trials in atherosclerotic cardiovascular disease (ASCVD) disease?

This product will be delivered within 3-5 business days.

Table of Contents

1 Preface
1.1 Introduction
1.2 Objectives of the Study
1.3 Research Methodology & Assumptions
2 Executive Summary
3 Overview of Atherosclerotic Cardiovascular Disease (ASCVD)
3.1 Signs and Symptoms
3.2 Causes
3.3 Risk Factors
3.4 Types of Atherosclerotic Cardiovascular Disease (ASCVD)
3.5 Diagnosis
3.6 Treatment
4 Patient Profile: Atherosclerotic Cardiovascular Disease (ASCVD)
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Atherosclerotic Cardiovascular Disease (ASCVD): Epidemiology Snapshot
5.1 Atherosclerotic Cardiovascular Disease (ASCVD) Incidence by Key Markets
5.2 Atherosclerotic Cardiovascular Disease (ASCVD) - Patients Seeking Treatment in Key Markets
6 Atherosclerotic Cardiovascular Disease (ASCVD): Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
7 Atherosclerotic Cardiovascular Disease (ASCVD): Key Facts Covered
7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
7.2 Top Countries Contributing to Clinical Trials in Europe
7.3 Top Countries Contributing to Clinical Trials in North America
7.4 Top Countries Contributing to Clinical Trials in Other Regions
8 Atherosclerotic Cardiovascular Disease (ASCVD), Drug Pipeline Assessment
8.1 Assessment by Treatment Type
8.2 Assessment by Route of Administration
8.3 Assessment by Drug Class
9 Drug Pipeline Comparative Analysis
9.1 List of Atherosclerotic Cardiovascular Disease (ASCVD) Pipeline Drugs
9.1.1 By Company
9.1.2 By Phase
9.1.3 By Indication
9.1.4 By Trial Status
9.1.5 By Funder Type
9.2 Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
10 Atherosclerotic Cardiovascular Disease (ASCVD) Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
10.1 Comparative Analysis for Late-Stage Drugs
10.1.1 Study Type
10.1.2 Recruitment Status
10.1.3 Company
10.1.4 Funder Type
10.2 Product Level Analysis*
10.2.1 Drug: Obicetrapib
10.2.1.1 Product Description
10.2.1.2 Trial ID
10.2.1.3 Sponsor Name
10.2.1.4 Study Type
10.2.1.5 Drug Class
10.2.1.6 Eligibility Criteria
10.2.1.7 Study Record Dates
10.2.1.7.1 First Submitted
10.2.1.7.2 First Posted
10.2.1.7.3 Last Update Posted
10.2.1.7.4 Last Verified
10.2.1.8 Indication
10.2.1.9 Study Design
10.2.1.10 Recruitment Status
10.2.1.11 Enrollment (Estimated)
10.2.1.12 Location Countries
10.2.1.13 Recent Results
10.2.2 Drug: Inclisiran sodium 300 mg
10.2.3 Drug: Olpasiran
10.2.4 Other Drugs
11 Atherosclerotic Cardiovascular Disease (ASCVD) Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
11.1 Comparative Analysis for Mid-Stage Drugs
11.1.1 Study Type
11.1.2 Recruitment Status
11.1.3 Company
11.1.4 Funder Type
11.2 Product Level Analysis*
11.2.1 Drug: AZD0780
11.2.1.1 Product Description
11.2.1.2 Trial ID
11.2.1.3 Sponsor Name
11.2.1.4 Study Type
11.2.1.5 Drug Class
11.2.1.6 Eligibility Criteria
11.2.1.7 Study Record Dates
11.2.1.7.1 First Submitted
11.2.1.7.2 First Posted
11.2.1.7.3 Last Update Posted
11.2.1.7.4 Last Verified
11.2.1.8 Indication
11.2.1.9 Study Design
11.2.1.10 Recruitment Status
11.2.1.11 Enrollment (Estimated)
11.2.1.12 Location Countries
11.2.1.13 Recent Results
11.2.2 Drug: CSL300
11.2.3 Other Drugs
12 Atherosclerotic Cardiovascular Disease (ASCVD) Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
12.1 Comparative Analysis for Early-Stage Drugs
12.1.1 Study Type
12.1.2 Recruitment Status
12.1.3 Company
12.1.4 Funder Type
12.2 Product Level Analysis*
12.2.1 Drug: AZD4144
12.2.1.1 Product Description
12.2.1.2 Trial ID
12.2.1.3 Sponsor Name
12.2.1.4 Study Type
12.2.1.5 Drug Class
12.2.1.6 Eligibility Criteria
12.2.1.7 Study Record Dates
12.2.1.7.1 First Submitted
12.2.1.7.2 First Posted
12.2.1.7.3 Last Update Posted
12.2.1.7.4 Last Verified
12.2.1.8 Indication
12.2.1.9 Study Design
12.2.1.10 Recruitment Status
12.2.1.11 Enrollment (Estimated)
12.2.1.12 Location Countries
12.2.2 Drug: VERVE-101
12.2.3 Other Drugs
13 Atherosclerotic Cardiovascular Disease (ASCVD) Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
13.1.1 Study Type
13.1.2 Recruitment Status
13.1.3 Company
13.1.4 Funder Type
13.2 Product Level Analysis*
13.2.1 Drug 1
13.2.1.1 Product Description
13.2.1.2 Trial ID
13.2.1.3 Sponsor Name
13.2.1.4 Study Type
13.2.1.5 Drug Class
13.2.1.6 Eligibility Criteria
13.2.1.7 Study Record Dates
13.2.1.7.1 First Submitted
13.2.1.7.2 First Posted
13.2.1.7.3 Last Update Posted
13.2.1.7.4 Last Verified
13.2.1.8 Indication
13.2.1.9 Study Design
13.2.1.10 Recruitment Status
13.2.1.11 Enrollment (Estimated)
13.2.1.12 Location Countries
13.2.2 Other Drugs
14 Atherosclerotic Cardiovascular Disease (ASCVD), Key Drug Pipeline Companies
14.1 Amgen
14.1.1 Company Snapshot
14.1.2 Pipeline Product Portfolio
14.1.3 Financial Analysis
14.1.4 Recent News and Developments
14.2 AstraZeneca
14.2.1 Company Snapshot
14.2.2 Pipeline Product Portfolio
14.2.3 Financial Analysis
14.2.4 Recent News and Developments
14.3 Novartis Pharmaceuticals
14.3.1 Company Snapshot
14.3.2 Pipeline Product Portfolio
14.3.3 Financial Analysis
14.3.4 Recent News and Developments
14.4 NewAmsterdam Pharma
14.4.1 Company Snapshot
14.4.2 Pipeline Product Portfolio
14.4.3 Financial Analysis
14.4.4 Recent News and Developments
14.5 CSL Behring
14.5.1 Company Snapshot
14.5.2 Pipeline Product Portfolio
14.5.3 Financial Analysis
14.5.4 Recent News and Developments
14.6 Verve Therapeutics, Inc.
14.6.1 Company Snapshot
14.6.2 Pipeline Product Portfolio
14.6.3 Financial Analysis
14.6.4 Recent News and Developments
15 Regulatory Framework for Drug Approval, By Region16 Terminated or Suspended Pipeline Products

Related Topics

Related Reports

Atherosclerotic Cardiovascular Disease (ASCVD) - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Atherosclerotic Cardiovascular Disease (ASCVD) - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 249 Pages
  • Global
From
Atherosclerosis - Pipeline Insight, 2025 - Product Image

Atherosclerosis - Pipeline Insight, 2025

  • Clinical Trials
  • 80 Pages
  • Global
From
Atherosclerosis Pipeline Analysis Report 2025 - Product Image

Atherosclerosis Pipeline Analysis Report 2025

  • Report
  • 200 Pages
  • Global
From
Atherosclerotic Cardiovascular Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Image

Atherosclerotic Cardiovascular Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • 139 Pages
  • Global
From
Atherosclerosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Image

Atherosclerosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • 243 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.